Innovative radioisotope therapy for patients with neuroendocrine tumors using an α (225Ac) emitter labeled somatostatin analog: octreotate. A promising new treatment for advanced progressive neuroendocrine neoplasms

Affiliations

• ¹ Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland
• ² Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland. zbigniew.j.krol@cskmswia.gov.pl
• ³ European Commission, Joint Research Centre, Karlsruhe, Germany
• ⁴ Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Warsaw, Poland